Published in Neuro Oncol on January 06, 2010
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol (2011) 1.89
Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol (2010) 1.05
Brain dendritic cells: biology and pathology. Acta Neuropathol (2012) 0.96
Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res (2012) 0.88
Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci (2011) 0.86
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflammation (2010) 0.85
Vaccines targeting the neovasculature of tumors. Vasc Cell (2011) 0.84
Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther (2013) 0.79
Immunotherapy for glioblastoma: a long and winding road. Neuro Oncol (2010) 0.78
Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: a case report. World J Surg Oncol (2014) 0.77
Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy. Cancers (Basel) (2011) 0.77
The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. Oncoimmunology (2015) 0.75
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
FOXP3: of mice and men. Annu Rev Immunol (2006) 6.89
TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med (2005) 6.87
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res (2005) 2.83
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
Regulatory T cells and cancer. Curr Opin Immunol (2007) 2.41
Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol (2001) 2.38
Taming cancer by inducing immunity via dendritic cells. Immunol Rev (2007) 1.92
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res (2005) 1.76
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci (2006) 1.74
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res (2006) 1.64
Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol (2004) 1.48
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res (2006) 1.42
Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res (2003) 1.35
Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech (2001) 1.30
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A (1996) 1.30
Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 1.28
How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood (2005) 1.12
Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther (2006) 1.07
The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol (2003) 1.04
Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer (2000) 1.02
Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer (2005) 1.00
Dendritic cells amplify T cell-mediated immune responses in the central nervous system. J Immunol (2006) 0.99
Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res (2007) 0.99
Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol (2005) 0.98
Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta (2007) 0.97
Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett (2001) 0.96
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery (2006) 0.92
Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother (2003) 0.92
Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther (2005) 0.91
Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer (2007) 0.90
Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res (2005) 0.89
Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther (2004) 0.88
Modification of the tumor microenvironment to enhance immunity. Front Biosci (2007) 0.86
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol (2005) 0.86
Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother (2002) 0.82
An essential role for TNF in modulating thresholds for survival, activation, and tolerance of CD8+ T cells. J Immunol (2007) 0.81
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol (2009) 1.88
A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest (2007) 1.67
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol (2009) 1.46
Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J Exp Med (2010) 1.35
Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell (2011) 1.31
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. Cancer Res (2005) 1.24
Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol (2010) 1.21
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res (2007) 1.19
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer (2010) 1.16
A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med (2008) 1.16
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget (2012) 1.15
TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest (2015) 1.12
Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol (2007) 1.10
The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol Dis (2005) 1.08
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
Primary primitive peripheral neuroectodermal tumor of the prostate. Immunophenotypic and molecular study of a case. Arch Pathol Lab Med (2003) 1.06
Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neurosci Lett (2004) 1.05
Homozygous DNA ligase IV R278H mutation in mice leads to leaky SCID and represents a model for human LIG4 syndrome. Proc Natl Acad Sci U S A (2010) 1.04
Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. J Allergy Clin Immunol (2011) 1.03
Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med (2010) 1.03
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res (2014) 1.02
Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res (2006) 1.01
Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res (2014) 1.00
Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology (2009) 1.00
Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer (2002) 1.00
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol (2014) 0.99
Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am J Pathol (2010) 0.97
Evidence for non-homologous end joining and non-allelic homologous recombination in atypical NF1 microdeletions. Hum Genet (2004) 0.93
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One (2012) 0.91
Activin A induces Langerhans cell differentiation in vitro and in human skin explants. PLoS One (2008) 0.91
DNA damage in mammalian neural stem cells leads to astrocytic differentiation mediated by BMP2 signaling through JAK-STAT. Stem Cell Reports (2013) 0.91
Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol (2002) 0.91
FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. Oncotarget (2012) 0.90
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One (2013) 0.89
Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer (2003) 0.89
A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother (2011) 0.89
Gene signatures associated with mouse postnatal hindbrain neural stem cells and medulloblastoma cancer stem cells identify novel molecular mediators and predict human medulloblastoma molecular classification. Cancer Discov (2012) 0.89
Reelin affects chain-migration and differentiation of neural precursor cells. Mol Cell Neurosci (2009) 0.89
Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol (2013) 0.89
Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Neurosurg Rev (2015) 0.89
Of Omenn and mice. Trends Immunol (2008) 0.89
Synaptophysin I selectively specifies the exocytic pathway of synaptobrevin 2/VAMP2. Biochem J (2007) 0.88
MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics (2009) 0.88
Abnormalities of thymic stroma may contribute to immune dysregulation in murine models of leaky severe combined immunodeficiency. Front Immunol (2011) 0.88
Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol (2010) 0.88
Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol Ther (2012) 0.87
FABP4 is a candidate marker of cerebellar liponeurocytomas. J Neurooncol (2012) 0.86
Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer (2006) 0.86
Evolutionary genomic remodelling of the human 4q subtelomere (4q35.2). BMC Evol Biol (2007) 0.86
High doses of cobalt induce optic and auditory neuropathy. Exp Toxicol Pathol (2012) 0.86
Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro Oncol (2007) 0.86
Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur J Cancer (2010) 0.86
The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene (2003) 0.85
DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. Oncologist (2011) 0.85
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. Expert Rev Anticancer Ther (2011) 0.84
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology (2013) 0.84
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun (2015) 0.84
ζ Chain-associated protein of 70 kDa (ZAP70) deficiency in human subjects is associated with abnormalities of thymic stromal cells: Implications for T-cell tolerance. J Allergy Clin Immunol (2012) 0.83
KLF6 is not the major target of chromosome 10p losses in glioblastomas. Int J Cancer (2004) 0.83
Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology (2012) 0.83
Rai is a new regulator of neural progenitor migration and glioblastoma invasion. Stem Cells (2012) 0.83
Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. J Neurooncol (2005) 0.82
Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. J Neuroimmunol (2013) 0.81
An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. PLoS One (2012) 0.81
Dendritic cell vaccines for cancer stem cells. Methods Mol Biol (2009) 0.80
Dynamic Activity of miR-125b and miR-93 during Murine Neural Stem Cell Differentiation In Vitro and in the Subventricular Zone Neurogenic Niche. PLoS One (2013) 0.80
Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models. Dis Model Mech (2013) 0.80
Genetic signature of adult gliomas and correlation with MRI features. Expert Rev Mol Diagn (2009) 0.80
Uncommon Alu-mediated NF1 microdeletion with a breakpoint inside the NF1 gene. Genomics (2005) 0.79
Erratum to: Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Neurosurg Rev (2015) 0.79
Brain engraftment and therapeutic potential of stem/progenitor cells derived from mouse skin. J Gene Med (2006) 0.79
Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neuro Oncol (2006) 0.78
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. J Neurooncol (2014) 0.78
Caveolins in rhabdomyosarcoma. J Cell Mol Med (2011) 0.78
Hypomorphic mutation in the RAG2 gene affects dendritic cell distribution and migration. J Leukoc Biol (2013) 0.78
Radiation-induced glioblastoma in a medulloblastoma patient: a case report with molecular features. Neuropathology (2008) 0.77
Operability of glioblastomas: "sins of action" versus "sins of non-action". Neurol Sci (2013) 0.77
From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment. World Neurosurg (2010) 0.76
Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatment. Int J Radiat Oncol Biol Phys (2006) 0.76